3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
307
Lung Neoplasms
111
Adenocarcinoma of Lung
23
Non-Squamous Non-Small Cell Lung Cancer
21
Neoplasms
21
Adenocarcinoma, Bronchiolo-Alveolar
15
Brain Neoplasms
14
Neoplasm Metastasis
10
Squamous Cell Carcinoma of Head and Neck
5
Respiratory Tract Diseases
5
Carcinoma
5
Breast Neoplasms
5
Adenocarcinoma
5
Thoracic Neoplasms
4
Recurrence
4
Pancreatic Neoplasms
4
NSCLC
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Salivary Gland Neoplasms
3
Respiratory Tract Neoplasms
3
Rectal Neoplasms
3
Lung Diseases
3
Esthesioneuroblastoma, Olfactory
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Thymoma
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pleural Effusion, Malignant
2
Interventions
Surveys and Questionnaires
5
Nivolumab
5
pembrolizumab
3
atezolizumab
3
Radiosurgery
3
pralsetinib
2
pertuzumab
2
cobimetinib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Exercise
2
Drug Therapy
2
trastuzumab deruxtecan
1
trametinib
1
tepotinib
1
talazoparib
1
selpercatinib
1
repotrectinib
1
remune
1
ponatinib
1
pemigatinib
1
pazopanib
1
palbociclib
1
osimertinib
1
motexafin gadolinium
1
montanide ISA 51
1
itacitinib
1
ipatasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Erlotinib Hydrochloride
×
Thoracic
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled